Kaiser P
Acta Physiol Scand Suppl. 1984;536:1-53.
The major findings of the present study may be summarized as follows: Muscle strength, measured as maximal isokinetic torque and maximal dynamic muscle power, measured as the highest 5 s power output during a 30 s maximal cycle exercise test, were unaltered by beta-blockade. When maximal exercise was prolonged to 30-60 s, anaerobic endurance, measured both as average power during 30 s maximal cycle exercise and as static endurance time at 65% of maximal voluntary contraction force, was decreased by beta-blockade. On the other hand, anaerobic endurance measured as peak torque decline during 50 repeated maximal isokinetic contractions was unaffected by beta-blockade. Aerobic power, measured as maximal oxygen uptake (VO2max) during cycle exercise, was decreased by beta-blockade. In addition, aerobic endurance was decreased by beta-blockade when measured as both time to fatigue during 10 min cycling and as time for a 2000 m run. When comparing the effects of beta 1-selective and non-selective beta-blockade on work capacity, no differences were demonstrated with regard to muscle strength, muscle power, and aerobic power (VO2max). Aerobic endurance was decreased to a greater extent by non-selective than by beta 1-selective blockade, when similar reductions in heart rate and VO2 max were attained. The difference in aerobic endurance between the two types of blockers indicates that factors other than an effect on oxygen transport, are responsible for the further reduction in endurance induced by the non-selective blockade. These factors are most likely local metabolic factors. Similarly, work capacity was reduced to a greater extent by non-selective than beta 1-selective blockade when similar reduction in blood pressure were attained by both drugs in hypertensive patients. Muscle G-6-P concentration was reduced by non-selective, but not by beta 1-selective blockade, suggesting a beta 2-mediated retardation of glycolysis. The effects of beta-blockade on VO2max and work capacity shown during acute administration persisted during long-term treatment.
以最大等速扭矩衡量的肌肉力量以及以30秒最大周期运动测试中最高5秒功率输出衡量的最大动态肌肉功率,不受β受体阻滞剂的影响。当最大运动延长至30 - 60秒时,以30秒最大周期运动中的平均功率以及以最大自主收缩力的65%时的静态耐力时间衡量的无氧耐力,会因β受体阻滞剂而降低。另一方面,以50次重复最大等速收缩过程中的峰值扭矩下降衡量的无氧耐力不受β受体阻滞剂的影响。以周期运动中的最大摄氧量(VO2max)衡量的有氧功率,会因β受体阻滞剂而降低。此外,以10分钟骑行中的疲劳时间以及2000米跑步时间衡量的有氧耐力,会因β受体阻滞剂而降低。在比较β1选择性和非选择性β受体阻滞剂对工作能力的影响时,在肌肉力量、肌肉功率和有氧功率(VO2max)方面未显示出差异。当心率和VO2max有相似程度的降低时,非选择性β受体阻滞剂比β1选择性阻滞剂更能降低有氧耐力。两种类型阻滞剂在有氧耐力方面的差异表明,除了对氧运输的影响外,其他因素也导致了非选择性阻滞剂引起的耐力进一步降低。这些因素很可能是局部代谢因素。同样,在高血压患者中,当两种药物使血压有相似程度的降低时,非选择性β受体阻滞剂比β1选择性阻滞剂更能降低工作能力。非选择性β受体阻滞剂可降低肌肉G - 6 - P浓度,但β1选择性阻滞剂则不会,这表明糖酵解存在β2介导的延迟。急性给药时显示的β受体阻滞剂对VO2max和工作能力的影响在长期治疗期间持续存在。